Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The hypothesis under evaluation is that fesotorodine may provide clinical benefit in the treatment of the condition of stress urinary incontinence

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Fesoterodine

Criteria

Inclusion Criteria:

• Female, 18 - 65 years

• SUI symptoms for longer than 3 months

• Subjects must be non-pregnant and not breastfeeding

Exclusion Criteria:

• Disease or medical condition affecting the bladder or urinary tract (other tan stress urinary incontinence)

• Subjects taking medication with effects on the bladder or urinary tract

• Subejcts with medical conditions which could be adversely affected by administration of fesoterodine - gastrointestinal tract disease, glaucoma, hepatic impairment